Healthcare

醫藥業代代表製藥公司，透過即時、準確、可靠且科學化的服務，全力支持各個專長領域的醫生，以獲得最高的滿意度。Sales representative is representing pharmaceutical company to provide physicians across therapy areas with services to support them in attaining the goals with the highest satisfaction, by providing timely, accurate and reliable scientific engagement and services.

肺阻塞佔世界死因排名第四，預估將持續攀升。越來越多國際藥廠投入相關治療用藥，市場也發生了明顯的變化。LABA聯合LAMA將取代ICS聯合LABA FDC，成為肺阻塞的主要治療選擇並持續增長。而ICS聯合LABA FDC在氣喘治療的競爭更加激烈，差異化需求逐漸增加。
Chronic obstructive pulmonary disease (COPD) is now the fourth leading cause of death worldwide and is predicted by WHO to become the third by 2030. More and more international pharmaceuticals have increased investment in treatments for respiratory diseases, bringing significant changes to COPD and Asthma treatment market. LABA/LAMA has replaced ICS/LABA FDC to become the leading treatment choice for COPD and will continue its growth. We also found Increased competition of ICS/LABA FDC as asthma treatment, as well as the needs for differentiation.